ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

EVG Evgen Pharma Plc

0.80
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.80 0.75 0.85 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 422k -4.04M -0.0147 -0.54 2.2M
Evgen Pharma Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 0.80p. Over the last year, Evgen Pharma shares have traded in a share price range of 0.75p to 4.05p.

Evgen Pharma currently has 274,888,117 shares in issue. The market capitalisation of Evgen Pharma is £2.20 million. Evgen Pharma has a price to earnings ratio (PE ratio) of -0.54.

Evgen Pharma Share Discussion Threads

Showing 1676 to 1698 of 13025 messages
Chat Pages: Latest  77  76  75  74  73  72  71  70  69  68  67  66  Older
DateSubjectAuthorDiscuss
30/4/2020
14:18
Hi pennyfalls. Quite so! The next few weeks will tell us what we need to know here. Having effectively written my investment off here, I am watching with some interest, but cannot say I feel we have lost a heavy hitter, come what may.
lovewinshatelosses
30/4/2020
12:41
Hi,
I’m a total novice at shares and drug companies but this is my personal view. Having been on STEM Sfx01 and getting great results for me I find it incredibly frustrating that 12 months down from the results there has been no other progress or so it seems. I’m sure I read on here that they were looking at trying to make a tablet form due to the Giant capsule it was in. It wasn’t the smallest capsule but giant it wasn’t it was easy to take and to be fair I take a glucosamine tablet that is much bigger than the capsule. I know things take time but everything seems to be slow so I’m thinking a change in directorship could be a really good thing for the company to try and push things forward on all aspects. Please feel free to give me a polite bashing everyone if I’m talking rubbish! PS I’m well and starting my second new drug next week , it was delayed due to covid19 but we’re starting next week, fingers crossed for a long success on this one. Shielding is a pain but I’m quite liking the slower pace of life and the hubby isn’t divorced yet!! 😀

blakeysangel
30/4/2020
09:34
Lol, on the contrary, it's more suggestive that he's been forced out and someone more high profile or even potentially connected to a commercial JV will be announced soon, and news on their University collaborations could drop at anytime and every chance this could include SFX-01 being considered for Covid-19 trials. Gl ;-)

ps EVG's market cap is a lowly £12m and so plenty of potential UPside as good news rolls in....back to 10p plus in anticipation. ;-)

moneymunch
30/4/2020
09:27
CEO leaving having "decided to pursue other opportunities" is never a good sign. Says it all about the prospects here. Even 3p (where it was before the ramp) is too much.
sicilian_kan
30/4/2020
08:26
Well the market doesn't seem unduly concerned, and so fingers crossed for a high profile replacement waiting in the wings. Gla ;-)
moneymunch
30/4/2020
07:44
I think the answer might be what he hasn’t done.
pennyfalls
30/4/2020
07:32
Lol, yep, not quite the news i was expecting, no notice given and so was he pushed? Should be interesting how quickly his replacement is made, and if someone is already lined up. Gl ;-)
moneymunch
30/4/2020
07:22
Wow. What did he do?
lovewinshatelosses
29/4/2020
15:51
News at anytime and maybe due from their ongoing SFX-01 clinical drug collaborations , with Universities Dundee, Manchester & Rochester, all now heavily involved in Covid-19 research, and highly possible that they could have interest in SFX-01 as a potential compound for the treatment of Covid-19. Gla ;-)
moneymunch
29/4/2020
15:26
Strap yourselves in
peanut100
29/4/2020
14:48
Interesting indeed. Finncap pushing it better....
nobbygnome
29/4/2020
12:01
Decent reversal indeed, and 16p plus in a blink on a positive RNS, which could drop at anytime. Gl :-)
moneymunch
29/4/2020
11:56
Decent reversal off today's low. Does this mean that the correction off the recent high is over and that we are headed to a new high-possibly closing the gap around 16?
langland
20/4/2020
13:43
Don’t know about idiot ,definitely clever x
cammy5
20/4/2020
13:35
Errrrr nope not clever idiot
tialouise
20/4/2020
12:00
10 to 20 x your cash is that this century
cammy5
19/4/2020
21:26
Agree. Even higher in the current environment.
If one multiplies total invested capital GBP by 10X-20X return Y/number of shares, the upside will surely be very attractive.

mrwizard1
19/4/2020
08:53
Sorry I meant 5 to 10 times current price, 15p would be blown to pieces
peanut100
18/4/2020
21:49
15p would still be extremely under valued. True value only with acquisition by Big Pharma. Long tern investors will want at least 10X. I would be shocked if EVG were not quietly studying utility for COVID-19.
mrwizard1
18/4/2020
18:50
I agree that if they do announce something Covid related, at least 15p looks nailed on. That would close the gap nicely on the the chart.
nobbygnome
18/4/2020
17:05
I'd be surprised if EVG don't announce something very soon yes or no to confirm this like others have been releasing. If a yes looking at AVCT and SNG you'd think the price will be min 5 to 10 higher.
peanut100
18/4/2020
14:57
Cheers peanut100, " providing powerful anti-inflammatory and antioxidant protection in the lungs and airways" could be key on why EVG's Sulforadex might be considered for research and development for a potential treatment for respiratory problems associated with Covid-19, and perhaps a high chance that it will given the collaboration agreements they have with several universities that have been developing sulphoraphane based medicines with EVG, who are all now heavily involved in Covid-19 research and treatment development and so perhaps Sulfordex will be given consideration as a potential therapy compound with EVG's collaboration. Gl :-)
moneymunch
18/4/2020
11:41
Great article and find
peanut100
Chat Pages: Latest  77  76  75  74  73  72  71  70  69  68  67  66  Older

Your Recent History

Delayed Upgrade Clock